Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

RELIEF THERAPEUTICS HOLDING AG

(RLF)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

EQS-News: Relief Announces Implementation of New Share Subscription Facility with Main Shareholder GEM

01/21/2021 | 01:02am EST
EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Miscellaneous 
Relief Announces Implementation of New Share Subscription Facility with Main Shareholder GEM 
2021-01-21 / 07:00 
=---------------------------------------------------------------------------------------------------------------------- 
Relief Announces Implementation of New Share Subscription Facility with Main Shareholder GEM 
Geneva, Switzerland, January 21, 2021 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief" or the " 
Company"), a biopharmaceutical company with its lead compound RLF-100^TM (aviptadil) in advanced clinical development 
to treat severe COVID-19 patients, today announced that it has signed a binding agreement with the Company's main 
shareholder GEM Global Yield LLC SCS ("GEM") for the implementation of a new Share Subscription Facility ("SSF") in the 
amount of up to CHF 50 million. GEM is Relief's longest standing shareholder, dating back to their initial investment 
in 2015, and currently owns over 1.3 billion shares of Relief common stock. 
Under the terms of the SSF, Relief has the right to periodically, during a timeframe of up to three years, issue and 
sell shares to GEM. Under the facility, GEM undertakes to subscribe to or acquire ordinary registered RELIEF 
THERAPEUTICS Holding AG shares upon Relief's exercise of a draw down notice. In accordance with the customary terms of 
the SSF agreement, Relief will control the timing and maximum amount of any draw down, and retains the right, not the 
obligation, to draw down on the full commitment amount. Future subscription prices under the SSF will correspond to 90% 
of the average of the closing bid prices on the SIX Swiss Exchange during the reference period, which corresponds to 15 
trading days following Relief's draw down notice. 
Proceeds from the SSF drawdowns will be used to produce commercial quantities of RLF-100^TM (aviptadil) and acquire 
additional assets to expand and diversify Relief's drug pipeline. 
Raghuram (Ram) Selvaraju, Chairman of the Board of Relief, said: "Establishing a new SSF underlines GEM's commitment to 
and faith in Relief. This facility gives us increased flexibility to meet anticipated demand, should RLF-100^TM show 
positive results in the ongoing trial in critical COVID-19 patients and gain marketing authorization. It also enables 
us to move quickly, should we have opportunities to build our pipeline." 
"This additional financial commitment represents our support for Relief's plans to build the Company, as well as our 
dedication to the battle against COVID-19. As worldwide cases have soared to over 77 million, it is clear that new 
therapeutic options are urgently needed, especially for very sick patients. We believe that Relief is uniquely 
positioned to address COVID-19 induced lung injury as well as provide an important key to treating other respiratory 
illnesses," commented Chris Brown, Founder and Director of GEM. 
### 
ABOUT RELIEF 
Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a 
history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is 
concentrating its efforts on developing new treatments for respiratory disease indications. Its lead drug candidate 
RLF-100^TM (Aviptadil), synthetic vasoactive intestinal peptide (VIP), is being developed in collaboration with 
NeuroRx, Inc. and is currently being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in 
respiratory deficiency due to COVID-19. RLF-100^TM is believed to be the first COVID-19 therapeutic to demonstrate the 
ability to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis 
of cytokines in the lung. Since July 2020, severe COVID-19 patients have been treated with RLF-100^TM under U.S. FDA 
Emergency Use Investigational New Drug (IND) authorization and Expanded Access Protocol authorization for the treatment 
of respiratory failure in COVID-19. Relief also holds a patent issued in the United States and various other countries 
covering potential formulations of RLF-100^TM. 
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB 
under the symbol RLFTF. 
Follow us on LinkedIn 
CONTACT                                              FOR MEDIA/INVESTOR INQUIRIES: 
RELIEF THERAPEUTICS Holding AG                       MC Services AG 
Raghuram (Ram) Selvaraju, Ph.D., MBA                 Anne Hennecke / Brittney Sojeva 
Chairman of the Board                                Tel.: +49 (0) 211-529-252-14 
Mail: contact@relieftherapeutics.com                 Mail: relief@mc-services.eu Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. ----------------------------------------------------------------------------------------------------------------------- 

End of Media Release -----------------------------------------------------------------------------------------------------------------------

Language:     English 
Company:      RELIEF THERAPEUTICS Holdings AG 
              Avenue de Sécheron 15 
              1202 Genève 
              Switzerland 
E-mail:       contact@relieftherapeutics.com 
Internet:     https://relieftherapeutics.com 
ISIN:         CH0100191136 
Listed:       SIX Swiss Exchange 
EQS News ID:  1162121 
 
End of News   EQS Group News Service 
=---------- 

(MORE TO FOLLOW) Dow Jones Newswires

January 21, 2021 01:01 ET (06:01 GMT)

All news about RELIEF THERAPEUTICS HOLDING AG
01:23aRelief Therapeutics Appoints Chief Medical Officer, Other Executives
MT
01:03aRelief Therapeutics Announces Executive Changes
EQ
11/29Relief Therapeutics Partner NRx Says Zyesami Outperforms Remdesivir in Critical COVID-1..
MT
11/29Relief Reports U.S. Collaboration Partner Identifies Significantly Higher Likelihood of..
EQ
11/24Relief Therapeutics Joins InveniAI to Develop New Drug Candidates For Rare Diseases
MT
11/24US FDA Denies Breakthrough Therapy Designation For Relief Therapeutics' COVID-19 Drug
MT
11/24Relief Therapeutics and InveniAI Sign a Strategic Collaboration Agreement to Identify N..
EQ
11/24RELIEF THERAPEUTICS Holding SA and InveniAI Sign A Strategic Collaboration Agreement to..
CI
11/24Relief Reports that its U.S. Collaboration Partner has Announced the U.S. Food and Drug..
EQ
11/18Relief Therapeutics to Start Trading on OTC Market in US
MT
More news
Financials
Sales 2021 1,00 M 1,08 M 1,08 M
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 296 M 321 M 320 M
Capi. / Sales 2021 296x
Capi. / Sales 2022 14,8x
Nbr of Employees 10
Free-Float 63,1%
Chart RELIEF THERAPEUTICS HOLDING AG
Duration : Period :
Relief Therapeutics Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RELIEF THERAPEUTICS HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 0,07 CHF
Average target price 0,52 CHF
Spread / Average Target 674%
Managers and Directors
Jack M. Weinstein Chief Financial Officer & Treasurer
Raghuram Selvaraju Chairman
Gilles Della Corte Chief Medical Officer
Taneli Jouhikainen Chief Operating Officer
Jeremy Meinen Vice President-Finance & Administration
Sector and Competitors
1st jan.Capi. (M$)
RELIEF THERAPEUTICS HOLDING AG-75.02%321
MODERNA, INC.252.74%149 412
LONZA GROUP AG28.41%58 671
IQVIA HOLDINGS INC.48.85%50 948
SEAGEN INC.-5.61%30 228
CELLTRION, INC.-40.81%24 321